Cariprazine Solid Dispersion Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of Cariprazine suffer from premature degradation under different storage conditions, leading to reduced stability and bioavailability, with existing solutions requiring specialized excipients and complex processes to achieve desired stability and rapid drug release.
Innovation Solution
Development of stable solid oral formulations using a premix/solid dispersion of Cariprazine with conventional excipients like microcrystalline cellulose, maltodextrin, and sucrose, which provide rapid drug release and improved bioavailability without the need for low water activity excipients or pH adjustments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional excipients with high water activity are used in Cariprazine formulations, then the formulation is easy to manufacture and has good bioavailability, but the Cariprazine undergoes hydrolytic degradation leading to reduced stability
Solution Approach 1:
The patent introduces an intermediary substance (excipient with low water activity) that mediates between the drug and the harmful hydrolytic environment. This intermediary absorbs water and creates a protective microenvironment, preventing direct contact between water and Cariprazine while maintaining overall formulation manufacturability and bioavailability.
Solution Approach 2:
The patent changes the water activity parameter of the formulation by selecting excipients with low water activity. This parameter change fundamentally alters the hydrolytic degradation pathway, reducing it to negligible levels while preserving other critical formulation properties such as manufacturability and bioavailability.
2Stability of the object's composition
If specialized excipients with low water activity are used to improve stability, then hydrolytic degradation is reduced, but the formulation complexity and manufacturing difficulty increase
Solution Approach 1:
The patent identifies excipients that serve multiple functions simultaneously: they provide low water activity to prevent hydrolysis, maintain acceptable bioavailability, and facilitate manufacturing. This multi-functionality reduces the need for complex formulation designs and multiple specialized components.
Solution Approach 2:
The patent employs conventional, readily available excipients rather than expensive, specialized stabilizing agents. These common excipients provide sufficient protection against hydrolysis without requiring complex formulation techniques or expensive materials, simplifying the overall formulation approach.
3Stability of the object's composition
If pH adjustment is used to enhance Cariprazine stability by reducing ionization, then hydrolysis is inhibited, but the formulation complexity and potential interactions increase
Solution Approach 1:
The patent extracts the pH adjustment step from the formulation process and replaces it with a water activity-based approach. By removing the need for pH modification, the formulation avoids the complexity of buffer systems and potential pH-related interactions while achieving equivalent stability protection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations demonstrate enhanced stability with less than 0.5% hydrolysis degradation product after 6 months, maintaining bioequivalence to marketed Cariprazine capsules and ensuring commercially viable, easy-to-manufacture products with improved bioavailability and stability profiles.
Implementation Method 1
degradation of the active ingredient mainly depends upon the amount of free water released from the excipient
Implementation Method 2
the stability of Cariprazine depends on the solid state microenvironmental pH of the formulation, wherein rising of pH enhances stability of Cariprazine by reducing ionization of the weakly basic drug
Data Source
AI summary
The present invention relates to stabilized pharmaceutical formulations comprising therapeutically effective amount of Cariprazine premix/solid dispersion, or its pharmaceutically acceptable salts, esters, hydrates and solvates thereof, at least one diluent which is not having low water activity and optionally one or more excipients selected from lubricant, disintegrant and buffering agent or combinations thereof. The present invention further relates to process for preparation and method of using such stable formulations comprising Cariprazine.